Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 10q

Re: 10q

in response to by
posted on Mar 13, 2010 01:23PM

I hate to say it, but I think the 10q is unlikely to deliver anything that will move share price unless the CAT signing shows some escalation in license fees. Framed by positive results by the PTO, settlement on the ARS front, New impressive licensees, and PDSG news and the quarterly's will not become important for share price appreciation for awhile. IMO I feel it is quite possible that with the possibilities that lie ahead we could become a story stock again. I know this seems overly optYmistic but it is quite possible that all of this could be bunched tightly enough, calendar wise, to grab alot of attention. The calendar could just as easily remain blank but I prefer the sunnyside today. good luck

Share
New Message
Please login to post a reply